<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03961516</url>
  </required_header>
  <id_info>
    <org_study_id>20181150</org_study_id>
    <nct_id>NCT03961516</nct_id>
  </id_info>
  <brief_title>Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis</brief_title>
  <acronym>CFCGM</acronym>
  <official_title>Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the utility of a continuous glucose monitor
      device (CGM) in screening for cystic fibrosis related diabetes. The investigators will also
      study how fat deposition in the pancreas and liver impacts insulin production and response,
      as measured by a frequently sampled oral glucose tolerance test.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cystic Fibrosis Related Diabetes (CFRD) occurs in 20% of adolescents and 30-40% of adults
      with cystic fibrosis. CFRD is associated with reduced lung function, lower body mass index,
      and increased mortality. The CF Foundation recommends yearly Oral Glucose Tolerance Test
      (OGTT) for all CF patients beginning at age 10 years. Unfortunately adherence to screening
      recommendations is poor, with fewer than 50% of the eligible CF patients completing OGTT each
      year. Additionally, the OGTT has been criticized for poor reproducibility and for not
      accurately reflecting real-life glycemic excursions.

      The FreeStyle Libre Pro is a blinded CGM that can record up to 14 days of home-living glucose
      data on one sensor. This quarter-sized device is placed on the upper arm and requires no
      fingerstick calibrations. Multiple studies have demonstrated the utility of CGM in CF
      patients, but no study has determined the utility of CGM in replicating the results of an
      OGTT. The use of CGM in CFRD screening has the potential to reduce screening burden, increase
      screening adherence and provide useful information about home glycemic excursions.

      Pancreatic steatosis is common in CF with complete pancreatic fat replacement occurring in
      some cases. Pancreatic steatosis is also seen in patients with type 2 diabetes and may impact
      insulin secretion or the rate of beta cell decline. MRI is the most sensitive tool for
      detecting pancreatic steatosis. Ferrozzi described four patterns of pancreatic fat
      replacement in CF patients: (1) diffusely hyperintense with variable lobular pattern, (2)
      homogenous hyperintensity without lobular pattern, (3) hyperintense parenchyma with focal
      hypointensity, and (4) no structural or signal intensity changes. No studies have directly
      compared the degree of pancreatic steatosis with OGTT derived measures of insulin secretion
      or glycemic excursions on CGM.

      Hepatic steatosis is also common in CF patients and has an unclear impact on insulin
      sensitivity. Outside of CF, hepatic steatosis is associated with insulin resistance.

      This study has two aims:

      Aim 1: Determine how closely the FreeStyle Libre Pro CGM can replicate the results of an
      in-clinic oral glucose tolerance test.

      Aim 2: Explore whether pancreatic and hepatic steatosis correlated with insulin secretion and
      sensitivity in CF patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic agreement between plasma glucose and CGM</measure>
    <time_frame>baseline</time_frame>
    <description>Difference between blood glucose and CGM result will be calculated for each time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pancreatic Fat and Glycemic measures</measure>
    <time_frame>baseline</time_frame>
    <description>Correlation between the degree of pancreatic fat replacement (Class 1-4 and fat fraction) and measures of beta cell function on glucose tolerance testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGM results in CFRD vs. CFND</measure>
    <time_frame>baseline</time_frame>
    <description>Comparison of CGM parameters (time and excursions &gt;140mg/dL and &gt;200mg/dL between patients with insulin treated CFRD and no insulin treated CFRD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pancreatic Fat by Modulator Status</measure>
    <time_frame>baseline</time_frame>
    <description>Comparison of pancreatic fat (Ferrozzi category and fat fraction) in patients who are and are not receiving a CFTR modulator.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Cystic Fibrosis-related Diabetes</condition>
  <condition>Cystic Fibrosis Liver Disease</condition>
  <condition>Pancreatic Steatosis</condition>
  <condition>Hepatic Steatosis</condition>
  <arm_group>
    <arm_group_label>Cystic Fibrosis, Pancreatic Sufficient</arm_group_label>
    <description>CF patients with exocrine pancreatic sufficiency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cystic Fibrosis, Pancreatic Insufficient, No Insulin</arm_group_label>
    <description>CF patients with exocrine pancreatic insufficiency but not treated with insulin therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cystic Fibrosis, Pancreatic Insufficient, Treated with Insulin</arm_group_label>
    <description>CF patients with exocrine pancreatic insufficiency who are treated with insulin therapy for CFRD</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Frequently Sampled Oral Glucose Tolerance Test and CGM</intervention_name>
    <description>Patients will undergo a 2 hour frequently sampled oral glucose tolerance test while wearing an active FreeStyle Libre Pro sensor</description>
    <arm_group_label>Cystic Fibrosis, Pancreatic Insufficient, No Insulin</arm_group_label>
    <arm_group_label>Cystic Fibrosis, Pancreatic Insufficient, Treated with Insulin</arm_group_label>
    <arm_group_label>Cystic Fibrosis, Pancreatic Sufficient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MRI Pancreas and Liver</intervention_name>
    <description>Patients will undergo an MRI of the pancreas and liver</description>
    <arm_group_label>Cystic Fibrosis, Pancreatic Insufficient, No Insulin</arm_group_label>
    <arm_group_label>Cystic Fibrosis, Pancreatic Insufficient, Treated with Insulin</arm_group_label>
    <arm_group_label>Cystic Fibrosis, Pancreatic Sufficient</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cystic fibrosis will be recruited from the LeRoy W. Matthews CF Center at UH
        Cleveland Medical Center.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cystic fibrosis confirmed by sweat chloride or genetics

          -  Pancreatic insufficient or pancreatic sufficient

          -  No change in insulin status (either initiating or discontinuing) in the past 3 months

        Exclusion Criteria:

          -  CF liver disease with portal hypertension

          -  Systemic glucocorticoid exposure the past 2 weeks (does not include inhaled)

          -  Current pulmonary exacerbation treated with antibiotics

          -  Baseline or current FEV1 &lt;30% at time of recruitment

          -  Transplant recipient

          -  Pancreatic sufficient on insulin

          -  Started CFTR modulator in the past 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Kutney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katherine Kutney, MD</last_name>
    <phone>216-844-3661</phone>
    <email>katherine.kutney@uhhospitals.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Kutney, MD</last_name>
      <phone>216-844-3661</phone>
      <email>katherine.kutney@uhhospitals.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009 Sep;32(9):1626-31. doi: 10.2337/dc09-0586. Epub 2009 Jun 19.</citation>
    <PMID>19542209</PMID>
  </reference>
  <reference>
    <citation>Adler AI, Shine BS, Chamnan P, Haworth CS, Bilton D. Genetic determinants and epidemiology of cystic fibrosis-related diabetes: results from a British cohort of children and adults. Diabetes Care. 2008 Sep;31(9):1789-94. doi: 10.2337/dc08-0466. Epub 2008 Jun 5.</citation>
    <PMID>18535191</PMID>
  </reference>
  <reference>
    <citation>Annual Data Report 2016 Cystic Fibrosis Foundation Patient Registry [Internet]. Cystic Fibrosis Foundation Patient Registry. 2016</citation>
  </reference>
  <reference>
    <citation>Mainguy C, Bellon G, Delaup V, Ginoux T, Kassai-Koupai B, Mazur S, Rabilloud M, Remontet L, Reix P. Sensitivity and specificity of different methods for cystic fibrosis-related diabetes screening: is the oral glucose tolerance test still the standard? J Pediatr Endocrinol Metab. 2017 Jan 1;30(1):27-35. doi: 10.1515/jpem-2016-0184.</citation>
    <PMID>27977404</PMID>
  </reference>
  <reference>
    <citation>Walshaw M. Routine OGTT screening for CFRD - no thanks. J R Soc Med. 2009 Jul;102 Suppl 1:40-4. doi: 10.1258/jrsm.2009.s19009.</citation>
    <PMID>19605874</PMID>
  </reference>
  <reference>
    <citation>Li A, Vigers T, Pyle L, Zemanick E, Nadeau K, Sagel SD, Chan CL. Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor. J Cyst Fibros. 2019 Jan;18(1):144-149. doi: 10.1016/j.jcf.2018.07.010. Epub 2018 Aug 10.</citation>
    <PMID>30104123</PMID>
  </reference>
  <reference>
    <citation>Leclercq A, Gauthier B, Rosner V, Weiss L, Moreau F, Constantinescu AA, Kessler R, Kessler L. Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients. J Cyst Fibros. 2014 Jul;13(4):478-84. doi: 10.1016/j.jcf.2013.11.005. Epub 2013 Dec 17.</citation>
    <PMID>24359972</PMID>
  </reference>
  <reference>
    <citation>Franzese A, Valerio G, Buono P, Spagnuolo MI, Sepe A, Mozzillo E, De Simone I, Raia V. Continuous glucose monitoring system in the screening of early glucose derangements in children and adolescents with cystic fibrosis. J Pediatr Endocrinol Metab. 2008 Feb;21(2):109-16.</citation>
    <PMID>18422023</PMID>
  </reference>
  <reference>
    <citation>O'Riordan SM, Hindmarsh P, Hill NR, Matthews DR, George S, Greally P, Canny G, Slattery D, Murphy N, Roche E, Costigan C, Hoey H. Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study. Diabetes Care. 2009 Jun;32(6):1020-2. doi: 10.2337/dc08-1925. Epub 2009 Mar 11.</citation>
    <PMID>19279304</PMID>
  </reference>
  <reference>
    <citation>Jefferies C, Solomon M, Perlman K, Sweezey N, Daneman D. Continuous glucose monitoring in adolescents with cystic fibrosis. J Pediatr. 2005 Sep;147(3):396-8.</citation>
    <PMID>16182684</PMID>
  </reference>
  <reference>
    <citation>Della Corte C, Mosca A, Majo F, Lucidi V, Panera N, Giglioni E, Monti L, Stronati L, Alisi A, Nobili V. Nonalcoholic fatty pancreas disease and Nonalcoholic fatty liver disease: more than ectopic fat. Clin Endocrinol (Oxf). 2015 Nov;83(5):656-62. doi: 10.1111/cen.12862. Epub 2015 Aug 12.</citation>
    <PMID>26201937</PMID>
  </reference>
  <reference>
    <citation>Engjom T, Kavaliauskiene G, Tjora E, Erchinger F, Wathle G, Lærum BN, Njølstad PR, Frøkjær JB, Gilja OH, Dimcevski G, Haldorsen IS. Sonographic pancreas echogenicity in cystic fibrosis compared to exocrine pancreatic function and pancreas fat content at Dixon-MRI. PLoS One. 2018 Jul 26;13(7):e0201019. doi: 10.1371/journal.pone.0201019. eCollection 2018.</citation>
    <PMID>30048483</PMID>
  </reference>
  <reference>
    <citation>Ferrozzi F, Bova D, Campodonico F, De Chiara F, Uccelli M, Bacchini E, Grinzcich R, dè Angelis GL, Battistini A. Cystic fibrosis: MR assessment of pancreatic damage. Radiology. 1996 Mar;198(3):875-9.</citation>
    <PMID>8628886</PMID>
  </reference>
  <reference>
    <citation>Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology. 1999 Nov;30(5):1151-8.</citation>
    <PMID>10534335</PMID>
  </reference>
  <reference>
    <citation>Ayoub F, Trillo-Alvarez C, Morelli G, Lascano J. Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease. World J Hepatol. 2018 Jan 27;10(1):34-40. doi: 10.4254/wjh.v10.i1.34.</citation>
    <PMID>29399276</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>May 21, 2019</last_update_submitted>
  <last_update_submitted_qc>May 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Katherine Kutney</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatric Endocrinology</investigator_title>
  </responsible_party>
  <keyword>continuous glucose monitor</keyword>
  <keyword>cystic fibrosis</keyword>
  <keyword>cystic fibrosis related diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

